Next Article in Journal
Examining Short-Term Responses to a Long-Term Problem: RNA-Seq Analyses of Iron Deficiency Chlorosis Tolerant Soybean
Next Article in Special Issue
Signaling Through Purinergic Receptor P2Y2 Enhances Macrophage IL-1β Production
Previous Article in Journal
Osteochondral Regeneration Using Adipose Tissue-Derived Mesenchymal Stem Cells
Previous Article in Special Issue
Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice
Open AccessArticle

Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients

Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz University Hospital-UAM, 28040 Madrid, Spain
Internal Medicine, Infectious Diseases Division, Fundación Jiménez Díaz University Hospital-UAM, 28040 Madrid, Spain
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(10), 3590;
Received: 8 April 2020 / Revised: 15 May 2020 / Accepted: 18 May 2020 / Published: 19 May 2020
(This article belongs to the Special Issue Dissecting the Purinergic Signaling Puzzle)
Plasma levels of adenosine deaminase (ADA), an enzyme that deaminates adenosine to inosine, are increased during inflammation. An increase in ADA activity occurs with lower human immunodeficiency virus (HIV) viral load and higher CD4+ T cell counts. We aimed to investigate the role of plasma ADA as a biomarker of inflammation in treatment-naïve HIV patients who received tenofovir or another nucleoside analog for comparison. Ninety-two treatment-naïve patients were included in the study and grouped by treatment, i.e., tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) or Triumeq. ADA activity was measured in plasma and cytokines were analyzed by MILLIPLEX® MAP-Luminex® Technology. Plasma concentration of monocytes and neutrophils was measured at 0, 3, and 12 months post-treatment. Treatment-naïve HIV patients had increased ADA concentrations (over 15 U/L) that decreased after treatment with TAF and Triumeq, though this did not occur in TDF-treated patients. However, all groups exhibited a pro-inflammatory systemic profile at 12 months of treatment. Plasma GM-CSF levels decreased after 12 months of treatment in the TDF group, with a concomitant decrease in blood monocyte count, and a negative correlation with ADA values was found. In conclusion, ADA levels may be modulated by antiretroviral therapy in HIV patients, possibly affecting inflammatory status. View Full-Text
Keywords: tenofovir; adenosine deaminase; HIV; biomarker; inflammation tenofovir; adenosine deaminase; HIV; biomarker; inflammation
Show Figures

Graphical abstract

MDPI and ACS Style

Conesa-Buendía, F.M.; Llamas-Granda, P.; Atencio, P.; Cabello, A.; Górgolas, M.; Largo, R.; Herrero-Beaumont, G.; Mediero, A. Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients. Int. J. Mol. Sci. 2020, 21, 3590.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop